Medtronic receives CE Mark for Resolute Onyx stent

Medtronic has announced that its Resolute Onyx drug-eluting stent (DES) has been granted European CE Mark approval.

The first live patient implant of the Resolute Onyx DES occurred during the recent XII International Course of Endovascular and Myocardial Therapy event in Madrid, paving the way for its international launch.

It is the first stent to feature a new advancement called CoreWire Technology, which allows it to offer a denser core metal wrapped in a cobalt alloy outer layer, offering increased radiopacity, while its thinner struts improve deliverability without compromising strength.

The device also features a new delivery system with PowerTrac technology that provides superior and enhanced deliverability through challenging lesions.

Jason Weidman, vice-president and general manager of the coronary and renal denervation business unit at Medtronic, said: "The advancements of the Resolute Onyx DES specifically address the need for continued procedural efficiency and ease-of-use."

Last week, the firm commenced a new clinical trial of an investigational surgical aortic heart valve made from bovine pericardial tissue, which will involve up to 650 patients.